Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Exacerbations with Relvar
Asthma control isn’t just about reducing symptoms – it’s about reducing the likelihood of exacerbations too.
With Relvar, asthma patients can reduce their rate of exacerbations vs both BUD/Form and ICS, as proven in real-world and clinical settings, respectively.1,2
This graph has been independently created by GSK from the original data. The same results were first published in Bateman ED, et al. Thorax 2014;69:312–319.
Discover Relvar
Need help with this product?
Abbreviations
BUD, budesonide; CI, confidence interval; Form, formoterol; ICS, inhaled corticosteroid.
References
- Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.
- Bateman ED, et al. Thorax 2014;69:312–319.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230007 June 2023
